Blood test may spare gastric cancer patients from unnecessary chemo

NCT ID NCT06609759

Ongoing Disease control Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

First seen May 12, 2026 · Last updated May 25, 2026 · Updated 7 times

Summary

This study looks at whether using a blood test (ctDNA) to guide treatment after surgery for stage II-III gastric cancer works as well as standard chemotherapy. About 197 patients are being observed to see if those with low-risk blood markers can safely receive less intense treatment. The goal is to maintain cancer control while reducing side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE II-III GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Jinan Central Hospital,

Jinan, Shandong, China
Qilu Hospital of Shandong Univertisy

Jinan, Shandong, 250012, China
Shandong Provincial Hospital Affiliated to Shandong First Medical University

Jinan, Shandong, 250012, China
The Affiliated Hospital of Qingdao University

Qingdao, Shandong, 266000, China
Yantai Yuhuangding Hospital

Yantai, Shandong, 264000, China

Conditions

Explore the condition pages connected to this study.

STAGE II-III GASTRIC CANCER STAGE II-III GASTRIC CANCER